The current standard-of-care to treat melanoma heavily relies on drugs that inhibit the MEK and BRAF kinases to induce tumor regression by eliciting apoptotic cell death, or at minima to block tumor growth [2–4]. This evidence concerns the gene MAP2K7 and neoplasm.